

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

<https://marketpublishers.com/r/C56B1EA4E94EN.html>

Date: May 2016

Pages: 462

Price: US\$ 1,450.00 (Single User License)

ID: C56B1EA4E94EN

Abstracts

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target. The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 – 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R). Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan/MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia, Cyramza, Perjeta, Arrzera are also subject of biosimilar activities.

The report also addresses the slowly emerging second wave of biosimilar antibody activities against originator therapeutic antibodies such as abatacept, alemtuzumab, denosumab, eculizumab, omalizumab, pavilizumab, tocilizumab, and ustekinumab.

Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target/Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Contents

A) 2015 SALES OF THERAPEUTIC ANTIBODIES

Overview: 2015 Biologics Sales per Class of Products
Overview: 2015 Therapeutic Antibody Sales per Class of Products
Blockbuster Therapeutic Antibodies in 2015
Anti-TNF Antibody Sales in 2015
Cancer Antibody Sales in 2015
Other Anti-Inflammatory Antibody Sales in 2015
Ophthalmic Antibody Sales in 2015
Cardiometabolic & Anti-Infective Antibody Sales in 2015

B) BIOSIMILAR AND BIOSUPERIOR ANTI-TNF ANTIBODIES – 2016 UPDATE

1. Originator Anti-TNF Antibodies
 - Approved and Marketed Indications of anti-TNF Antibodies in Regulated Markets
 - 2015 SALES OF ANTI-TNF ANTIBODIES
 - Sales of Anti-TNF Antibodies in Q1/2016
 - Humira Pipeline of Recently Approved Indications & Upside Developments
 - Remicade Pipeline of Recent Approvals & Upside Indications
 - Enbrel Pipeline of Upside Indications
 - Simponi Pipeline of Recent Approvals & Upside Indications
 - Cimzia Pipeline of Recent Approvals & Upside Indications
 - Defense Strategies against Biosimilar Anti-TNF Antibodies
2. Biosuperior Anti-TNF Antibodies
 - Non-Antibody Anti-TNF Biosuperiors
 - Anti-TNF Biosuperior Antibodies
3. Biosimilar Anti-TNF Antibodies
 - Humira Biosimilar Antibodies:
 - Developments in Regulated Markets
 - Developments in Less Regulated Markets
 - Enbrel Biosimilar Antibodies:
 - Developments in Regulated Markets
 - Developments in Less Regulated Markets
 - Remicade Biosimilar Antibodies:
 - Developments in Regulated Markets
 - Developments in Less Regulated Market
 - Simponi & Cimzia Biosimilar Antibodies

C) BIOSIMILAR AND BIOSUPERIOR ANTI-VEGF/-R ANTIBODIES – 2016 UPDATE

- 1) Marketed Anti-VEGF/R Products in Oncology
 - Avastin, Zaltrap & Cyramza Sales 2008 – 2015
 - Avastin Sales and Indication Portfolio
 - Zaltrap Sales and Indication Portfolio
 - Cyramza Sales and Indication Portfolio
- 2) Anti-VEGF Biosuperiors of Avastin and Zaltrap
 - Anti-VEGF Biosuperior Pipeline in Oncology
 - Bispecific Anti-VEGF Pipeline in Oncology
- 3) Anti-VEGF-R Biosuperiors of Cyramza
 - Anti-VEGF-R Biosuperior Pipeline in Oncology
 - Bispecific Anti-VEGF-R Pipeline in Oncology
- 4) Avastin & Cyramza Biosimilar Pipeline in Oncology
- 5) Marketed Anti-VEGF Products in Ophthalmology
 - Lucentis & Eylea Sales 2008 – 2015
 - Lucentis Sales & Indication Portfolio
 - Eylea Sales & Indication Portfolio
- 6) Anti-VEGF Biosuperiors of Lucentis and Eylea
 - Biosuperior Anti-VEGF in Ophthalmology
 - Biosuperior Bispecific Anti-VEGF and Anti-VEGF Combinations in Ophthalmology
- 7) Other Anti-VEGF Molecules in Ophthalmology
- 8) Lucentis Biosimilars in Ophthalmology
- 9) Eylea Biosimilars in Ophthalmology
- 10) Off-Label Use of Anti-VEGF in Ophthalmology

D) BIOSIMILAR AND BIOSUPERIOR ANTI-HER2 ANTIBODIES – 2016 UPDATE

1. 2015 Anti-Her2 Antibody Sales
2. Originator Anti-Her2 Antibodies
 - Herceptin Approved Indications & Pipeline
 - Perjeta Approved Indications & Pipeline
 - Kadcyla Approved Indications & Pipeline
3. Biosuperior Anti-Her2 Antibodies
 - 3RD GENERATION ANTI-HER2 ANTIBODIES**
 - Bispecific Anti-Her2 Antibodies
 - Anti-Her2 Antibody-Drug Conjugates, Immunotoxins, Immunocytokines & Radiopharmaceuticals

4. Biosimilar Anti-Her2 Antibodies
 - Herceptin Biosimilar Antibodies
 - Developments in Regulated Markets
 - Development in Less Regulated Markets
5. Perjeta Biosimilar Antibodies

E) BIOSIMILAR AND BIOSUPERIOR ANTI-CD20 ANTIBODIES – 2016 UPDATE

1. 2015 Sales of Anti-CD20 Antibodies
2. Originator Anti-CD20 Antibodies
 - Rituxan/MabThera Approved Indications & Pipeline
 - Gazyva Approved Indications & Pipeline
 - Arzerra Approved Indications and R&D Pipeline
 - Zevalin Approved Indications
3. Biosuperior Anti-CD20 Antibodies
 - 3RD GENERATION ANTI-CD20 ANTIBODIES**
 - Bispecific Anti-CD20 Antibodies
 - Anti-CD20 Antibody-Drug Conjugates, Immunotoxins & Immunocytokines
4. Biosimilar Anti-CD20 Antibodies
 - Rituxan/MabThera Biosimilar Antibodies:
 - Developments in Regulated Markets
 - Developments in Less Regulated Markets
5. Arzerra Biosimilar Antibodies

F) BIOSIMILAR AND BIOSUPERIOR ANTI-EGF-R ANTIBODIES - 2016 UPDATE

1. Sales of Anti-EGF-R Antibodies
2. Originator Anti-EGF-R Antibodies
 - Erbix Approved Indications & Pipeline
 - Vectibix Approved Indications & Pipeline
 - Nimotuzumab Approved Indications & Pipeline
 - Portrazza Approved Indications & Pipeline
3. Biosuperior Anti-EGF-R Antibodies
 - 3RD GENERATION ANTI-EGF-R ANTIBODIES**
 - Bispecific Anti-EGF-R Antibodies
 - Anti-EGF-R Antibody Drug Conjugates
4. Biosimilar Anti-EGF-R Antibodies
 - Erbix Biosimilar Antibodies:
 - Developments in Regulated Markets

Developments in Less Regulated Markets

G) NEXT WAVE OF BIOSIMILAR ANTIBODIES – 2016 UPDATE

Abatacept Biosimilar Antibodies
Aletuzumab Biosimilar Antibodies
Denosumab Biosimilar Antibodies
Eculizumab Biosimilar Antibodies
Omalizumab Biosimilar Antibodies
Palivizumab Biosimilar Antibodies
Tocilizumab Biosimilar Antibodies
Ustekinumab Biosimilar Antibodies
Biosimilars of Immune Checkpoint Inhibitor Antibodies

H) CORPORATE BIOSIMILAR & BIOSUPERIOR THERAPEUTIC ANTIBODY PIPELINES

COMPENIES MENTIONED IN THE REPORT

3SBio (Shenyang Sunshine Pharmaceutical Co)
AbbVie
AbClon
Ablynx
AET Biotech
Affibody
Affilogic
Affimed Therapeutics
Affitech
Allergan
Alopexx Oncology
Alteogen
Alvogen
Ambrx
Amega Biotech
Amgen
AngioChem
Apexigen
Aprogen
Archemix

AREVA Med
Aryogen
Ascendis Pharma
AstraZeneca (MedImmune)
Avaxia Biologics
AVEO Pharmaceuticals
Axxo
Baliopharm
Baxalta
Bayer
Binex
Bio Farma
biOasis Technologies
Biocad
BioCND
Biocon
Bioeq
Biogen
Bionovis
BioXpress Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Celltrion
Centrose
Ceres Oncology
Chengdu Kanghong Biotech Co.
CIMAB
Cipla
Clearside Biomedical
Coherus Biosciences
Complicx
Cristalia
Curaxys
CytomX Therapeutics
Daewoong Pharmaceutical Co
Daiichi Sankyo
Delenex Therapeutics
Dermira

Dong-A ST
Dr Reddy's Laboratories
Eddingpharma
Eisai
Eli Lilly
EnGenIC
Epirus Biopharmaceuticals
Esperance Pharmaceuticals
Exicure
Ferring Pharmaceuticals
ForSight VISION4
Fosun Pharma
Fujifilm Kyowa Kirin Biologics
Gansu Duiwei Biological Pharmaceutical Co
Gedeon Richter
Gene Techno Science (GTS)
Genllac
Genor Biopharma
Glenmark Pharmaceuticals
Gliknik
Glycotope
Green Cross
Halozyme
HanAll Pharmaceuticals
Hanwha Chemical Biologics Business
Harvest Moon Pharmaceuticals
Helvetic BioPharma
Hetero Group
Hyprocell
IBC Generium
Ildong Pharmaceutical
Immune Pharmaceuticals
ImmuneXcite
Immunomedics
Innogene Kalbiotech
Innokeys
Innovent Biologics
Intas Pharmaceuticals
Janssen (Johnson & Johnson)

JHL Biotech
Jiangsu Simcere Pharmaceutical
Jiangsu T-mab Biopharma
Kissei Pharmaceutical
Kyowa Hakko Kirin
LegoChem
LG Life Sciences
Libbs Farmaceutica
Mabion
MabTech
MabXience
MacroGenics
Meiji Seika
Merck (MSD)
Merck Biopharma & HealthCare Biosimilars
Merrimack Pharmaceuticals
Mersana Therapeutics
Merus
Mitsubishi Tanabe Pharma
Mochida
Molecular Partners
Molecular Templates
Momenta Pharmaceuticals
Mundipharma
Mycenax Biotech
Mylan Pharmaceuticals
Nanogen Biopharmaceutical Co
Natco Pharma
Neurotech
Nichi-iko Pharmaceutical
Nippon Kayaku
Novartis (& Sandoz/Alcon)
Oncobiologics
OncoMed Pharmaceuticals
Ophthea
Ophthotech
Orygen Biotecnologia
PanOptica
Paras Biopharmaceuticals

Pfenex
Pfizer (& Hospira)
PharmAbcine
Pharmamar
Pharmapraxis
Pieris Pharmaceuticals
PlantForm
Polpharma Group
Probiomed
Protalix Biotherapeutics
Ranbaxy
Regeneron Pharmaceuticals
Reliance Life Sciences
Roche
Samsung Bioepis (JV of Samsung and Biogen)
Sanofi
Senju Pharmaceutical
Shanghai Biomabs Pharmaceutical
Shanghai Celgen BioPharmaceutical Co
Shanghai Citi Pacific (CO) Guojian Pharmaceutical Co (CPGP)
Shanghai Fudan-Zhangjiang BioPharmaceuticals
Shanghai Henlius Biotech
Shanghai Zhangjiang Biotechnology (ZJ-Bio)
Sirnaomics
Sorrento Biologics/Therapeutics
Spectrum Pharmaceuticals
Stada Arzneimittel
STC Biologics
Syd labs
Symphogen
Synthon Biopharmaceuticals
Taisho Pharmaceutical
Takeda Pharmaceutical Co
TG Therapeutics
Therapeutics Protein International (TPI)
Tillots Pharma
Torrent Pharma
TPG Biologics
Trimer Biotech

Triphase Accelerator
TSH Pharma
Tyrogenex
UCB
Unum Therapeutics
Vaccinex
Valeant Pharmaceuticals
Valor Biotherapeutics
Wuhan YZY Biopharma
Xbrane Biopharma
Xencor
YL Biologics
Yuhan
Zhejiang Huahai Pharmaceutical Co
Zhejiang Medicine
Zova Biotherapeutics
Zydus Cadila
Zymeworks
Zyngenia

I would like to order

Product name: ?ompetitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

Product link: <https://marketpublishers.com/r/C56B1EA4E94EN.html>

Price: US\$ 1,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C56B1EA4E94EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970